These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1381 related items for PubMed ID: 19815292

  • 1. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 2. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 3. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 5. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [Abstract] [Full Text] [Related]

  • 8. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [Abstract] [Full Text] [Related]

  • 9. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
    [Abstract] [Full Text] [Related]

  • 10. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
    Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U.
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
    [Abstract] [Full Text] [Related]

  • 11. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
    Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N.
    Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
    [Abstract] [Full Text] [Related]

  • 12. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [Abstract] [Full Text] [Related]

  • 13. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration.
    Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, Prünte C, Schmidt-Erfurth U.
    Br J Ophthalmol; 2010 Feb; 94(2):185-9. PubMed ID: 19692384
    [Abstract] [Full Text] [Related]

  • 14. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [Abstract] [Full Text] [Related]

  • 15. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
    Keane PA, Chang KT, Liakopoulos S, Jivrajka RV, Walsh AC, Sadda SR.
    Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
    [Abstract] [Full Text] [Related]

  • 16. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.
    Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M.
    Retina; 2010 May; 30(7):1017-24. PubMed ID: 20224469
    [Abstract] [Full Text] [Related]

  • 17. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.
    Framme C, Panagakis G, Birngruber R.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1671-6. PubMed ID: 19875667
    [Abstract] [Full Text] [Related]

  • 18. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Mar; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
    Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP.
    Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
    [Abstract] [Full Text] [Related]

  • 20. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 May; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.